Mostrando 861 - 880 Resultados de 58,773 Para Buscar '"Her"', tiempo de consulta: 0.30s Limitar resultados
  1. 861
  2. 862
  3. 863
    por Ordan, Julien
    Publicado 2019
    “…Visit by Her Excellency Ms Ylva Johansson Minister for Employment Kingdom of Sweden…”
    Enlace del recurso
  4. 864
    por BRICE, Maximilien
    Publicado 2019
    “…Visit by Her Royal Highness Princess Maha Chakri Sirindhorn Kingdom of Thailand…”
    Enlace del recurso
  5. 865
    por Ordan, Julien
    Publicado 2019
    “…Visit by Her Excellency Ms Cecilia Jaber Breceda Ambassador of Mexico to Switzerland…”
    Enlace del recurso
  6. 866
    “…PURPOSE: The combination of trastuzumab and pertuzumab (HP) as part of a taxane-based regimen has shown benefit in the adjuvant and metastatic HER2+ breast cancer setting. In the CLEOPATRA trial, pruritus was reported in 11-17.6% of patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  7. 867
    por Beasley, Marcie, Daniel, Brooke
    Publicado 2023
    “…HER2 is overexpressed and/or amplified in approximately 20% of breast cancers. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  8. 868
    por Ariga, Shin
    Publicado 2023
    “…Human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase that belongs to the human epidermal growth factor receptor family. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  9. 869
    “…Besides that, holey graphyne is a potential HER catalyst with a low overpotential of 0.20 eV, which further reduces to 0.03 eV at 2% compressive strain.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  10. 870
    “…SIMPLE SUMMARY: HER2-positive breast cancer has an affinity for the central nervous system (CNS) manifested by metastases in both the brain parenchyma and the leptomeninges. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  11. 871
  12. 872
  13. 873
    “…More than 50% of breast cancers are currently defined as “Human epidermal growth factor receptor 2 (HER2) low breast cancer (BC)”, with HER2 immunohistochemistry (IHC) scores of +1 or +2 with a negative fluorescence in situ hybridization (FISH) test. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  14. 874
    “…The prognosis of local or locally advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer after a complete response from neoadjuvant systemic treatment (NAT) is excellent. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  15. 875
    “…Two syngeneic tumor models were used to estimate the in vivo antitumor activity of HER2 CAR-M and CD47 CAR-M. RESULTS: We constructed CAR-Ms targeting HER2 and CD47 and verified their phagocytic ability to ovarian cancer cells in vivo and in vitro. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  16. 876
  17. 877
    por Yang, Xin, Li, Yao, lu, Xu, Ren, Xiaotian, Hua, Bin
    Publicado 2023
    “…The aim of our study was to determine the frequency of low HER2 expression among HER2-negative breast cancers and compare the clinicopathological features and prognosis of HER2-low patients with those of HER2-zero patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  18. 878
    “…OBJECTIVE: This work sought to describe the influence of Marie Poussepin on Nursing from her vocation of service and charity. METHOD: Historical-hermeneutic study with participation by 15 Dominican Sisters of Charity in the Presentation of the Blessed Virgin from the city of Manizales and Bogotá, Colombia, who answered semi-structured interviews. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
  19. 879
  20. 880
    “…Epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and human epidermal growth factor receptor 2 (HER2) have been considered as potential therapeutic targets in cholangiocarcinoma, but no studies have yet clarified the clinicopathological or prognostic significance of these molecules. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
Herramientas de búsqueda: RSS